newsfilter
← Latest News
Business Wire·

Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth

ALC
  • Third-quarter 2026 net sales reached $2.7 billion, representing a 5% increase on both reported and constant currency bases compared to the same period in 2025.
  • Year-to-date 2026 sales totaled $8.2 billion, a 7% reported increase and 6% constant currency increase versus the first nine months of 2025.
  • Third-quarter 2026 diluted earnings per share (EPS) were $0.54, up 13% (14% constant currency), while core diluted EPS was $0.91, up 15% (15% constant currency).
  • Year-to-date diluted EPS declined 40% to $0.92 primarily due to a $287 million non-cash charge related to the discontinuation of PowerVision programs; core diluted EPS rose 14% to $2.60.
  • Surgical segment sales grew 4% in the third quarter to $1.5 billion, driven by Consumables (+6%) and Equipment/other (+11%), though Implantables fell 2%.
  • Vision Care segment sales increased 6% in the third quarter to $1.2 billion, led by Ocular health (+8%) and Contact lenses (+4%).
  • Alcon returned $748 million to shareholders year-to-date through dividends and share repurchases, including $210 million in the third quarter.
  • The company announced the acquisition of Neurotech Pharmaceuticals to strengthen its retinal disease portfolio with ENCELTO, the only FDA-approved treatment for Macular Telangiectasia Type 2.
  • Operating margin for the third quarter was 14.0%, while core operating margin improved to 21.8% from 20.2% in the prior year period.
  • The 2026 outlook was updated to project net sales growth of approximately 6% on a constant currency basis, with core operating margin growth narrowed to 100-150 basis points.
  • Efficiency measures expanded in November 2026 now estimate total costs of approximately $230 million with run-rate savings increased to $130 million.
  • Alcon received two 2026 Prix Galien USA nominations for the UNITY VCS system and TRYPTYR product.
  • The U.S. FDA approved BRYTLY Redness Reliever Eye Drops in October, expanding the company's consumer eye care offerings.
  • Free cash flow for the first nine months of 2026 was $1.3 billion, compared to $1.2 billion in the prior year period.
  • Net debt decreased to $2.94 billion as of September 30, 2026, from $3.13 billion at the end of 2025.